Real‐world data confirm elexacftor/tezacaftor/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis

Documenti analoghi

• Close monitoring and early intervention: management principles for cystic fibrosis in Denmark
  di: Tavs Qvist, et al.
  Pubblicazione: (2024)
• Real‐World Improvements of Lung Clearance Index and Ventilation Distribution Efficiency in Children With Cystic Fibrosis After Elexacaftor/Tezacaftor/Ivacaftor Initiation
  di: Esben Herborg Henriksen, et al.
  Pubblicazione: (2025)
• Arthritis in Cystic Fibrosis—Comparison of a Single‐Center Cohort and Published Case Reports/Series and a Review of the Literature
  di: Anne Sofie Rosenborg Peretz, et al.
  Pubblicazione: (2025)
• Disparities in elexacaftor/tezacaftor/ivacaftor initiation in the US cystic fibrosis population
  di: Kamyron Jordan, et al.
  Pubblicazione: (2024)
• Pregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis
  di: Paulette Magnas, et al.
  Pubblicazione: (2026)